Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Starbucks is going AI ..mentioned many will go w/AI in menu apps
Another coronavirus mutation was discovered – and this one might be more dangerous http://a.msn.com/05/en-us/BB1c4hoW?ocid=st
GL Brands On The Net..
Company website https://glbrands.com/
---
Instagram https://www.instagram.com/glbrandsinc/
https://www.instagram.com/greenlotushemp/
https://www.instagram.com/iriehemp/
---
GL Brands on YOUTUBE
..don't see it on any news sites ??
Good word..
.. yeah I was thinking Mind med awhile back at 35-40 it hit 4.35+ a few days ago.. ugh!! ..caught myself being loyal to the wrong ones again but it's also proof that all we need are a few big winners.. ;)
..and now she has free cable.
$NWBO Section 2 Financial Information Flash Works?
Item 2.01 Completion of Acquisition or Disposition of Assets
https://www.sec.gov/fast-answers/answersform8khtm.html
An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission (SEC). Also known as a Form 8-K, the report notifies the public of events reported including acquisition, bankruptcy, resignation of directors, or a change in the fiscal year. Nov 18 2019
------
https://www.millercanfield.com/resources-SEC-New-Material-Events.html
https://www.hklaw.com/en/insights/publications/2017/04/sec-issues-new-material-event-notices-under-propos
-------------
RE: I agree. But I sometimes wonder if NWBO will be sold on the cheap ($5 or so) and the new company will then release a shit load of PRs regarding UK, Germany, Europe, Canada RA endpoint change acceptance, FDA endpoint changes, Sawston buildout completion, Flaskworks technology implementation, DCVAX-L P3 TLD, etc. The stock will skyrocket...after retail shareholders are out of the picture.
This, perhaps, would explain why NWBO seldom announce new developments that shareholders find via their own dd. Why else wouldn't LP announce any of the above non-TLD new worthy events?! Please don't tell me she wants to prevent all of shorts from taking advantage of shareholders.
Quote:
I agree. However, I think the company will be sold before it can realize that price, as that kind of market cap is years down the line. But who knows?
$SSFT 'Monster~2021' - $0.0561 https://sonasoft.com
$SSFT 'Monster~2021' - $0.0561 https://sonasoft.com
Revive Therapeutics Ltd. (OTC: RVVTF) announced on November 18th, it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation and a specialty psychedelics pharmaceutical company, to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds.
"Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach," said Michael Frank, CEO of Revive.
"We are excited to advance the development of PharmaTher's recent discovery in the potential of psilocybin to treat certain cancers such as Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.
We are also leveraging PharmaTher's panaceAI™ discovery AI platform to discover new uses of undisclosed psychedelic compounds to be potentially used with our oral thin film delivery technology and expand our psychedelics drug pipeline."
$RVVTF replay - Bringing Psychedelics to Life With Revive Therapeurtics
$RVVTF Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin -
Talked to a number of people and they really like this delivery idea:
"Company has completed an oral thin-film strip product with psilocybin with dosage forms ranging between 1 mg and 20 mg"
https://ih.advfn.com/p.php?pid=nmona&article=83669647
..they could call it good early though.. pressure is on.. ;)
-clip- Dr. Youssef has contacted the FDA requesting that he be allowed to continue to administer inhaled Aviptadil for a couple more weeks. Her improvement has been amazing and he would like to see if it would continue with prolonged treatment. No response yet from the FDA
$RLFTF “While a lot of other experimental therapeutics are going to either live or die based on how the pandemic evolves, we feel on the contrary that once we have established this drug’s therapeutic utility in the context of Covid-19, hopefully, our long term vision is to have this drug become a sort of workhorse drug for emergency rooms and Intensive Care Units and hospitals and hospital systems everywhere.”
https://www.cnbc.com/2020/12/14/coronavirus-relief-therapeutics-shares-have-soared-38000percent-in-2020.html
$RLFTF A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year https://cnb.cx/2Wb0G9t
“... Selvaraju revealed that Relief Therapeutics and NeuroRx had been in contact with Operation Warp Speed and said if the drug successfully proves its efficacy in seriously ill patients following phase three randomized testing, the company expects to receive stockpiling orders on a similar scale to the likes of Gilead and Eli Lilly...”
$RLFTF A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year https://cnb.cx/2Wb0G9t
“... Selvaraju revealed that Relief Therapeutics and NeuroRx had been in contact with Operation Warp Speed and said if the drug successfully proves its efficacy in seriously ill patients following phase three randomized testing, the company expects to receive stockpiling orders on a similar scale to the likes of Gilead and Eli Lilly...”
$RLFTF RLF-100 Operation Warp Speed, Big Pharma let America down
https://www.bozemandailychronicle.com/opinions/letters_to_editor/operation-warp-speed-big-pharma-let-america-down/article_379734c4-cc70-5cd5-9e19-76d4ed05df19.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via @bozchron
..it's so insane.. could it be anything other than a blood diamond haul?
I thieved and reposted it on other sites w/prev. post also.. ;)
$RLFTF How an Agile Company Addressed the Pandemic: Moving from Psychiatric Medicines to a COVID-19 Therapeutic December 9, 2020 https://www.pharmasalmanac.com/articles/how-an-agile-company-addressed-the-pandemic-moving-from-psychiatric-medicines-to-a-covid-19-therapeutic
$RLFTF How an Agile Company Addressed the Pandemic: Moving from Psychiatric Medicines to a COVID-19 Therapeutic December 9, 2020
https://www.pharmasalmanac.com/articles/how-an-agile-company-addressed-the-pandemic-moving-from-psychiatric-medicines-to-a-covid-19-therapeutic
$RLFTF Good stuff !!
We have years of sufficient data/evidence to be deemed safe and effective. The current IV trial should receive EUA by next week according to other COVID drugs timelines after full enrollment.
We are WELL within the Nuremberg Code guidelines as some vaccines are clearly NOT. I feel we have the full scientific capacity to treat this entire pandemic from mild to critical swiftly and ethically.
By this time I would expect the FDA to come to this realization as the whole non-scientific, medically uneducated World is now discovering based only on RESULTS that no other therapeutic has even come close, showing little to NO positive results thus far.
These vaccines appear to be far from meeting the Nuremberg Code guidelines as well. (see my previous post).
https://www.zerohedge.com/medical/ex-pfizer-exec-demands-eu-halt-covid-19-vaccine-studies-over-indefinite-infertility-and
-allheartrader
'A' remains hospitalized with intubation now at Providence MC. SOC only, they will not discuss RLF or other 'treatments''.
A^^H*les!!!!!!!!!!!!!!!!!
That's the goal.. "is turning many people away from here"
$RLFTF "YOU TELL ME" - Dr. Javitt's / World Leading Hospitals Conference: COVID-19 Pandemic
Health care workers, Investors and others are fed up and moving on social media into action.. the info war is on.. people are done waiting..
$RLFTF (related) As Arizona Officials Push Vaccines Promising Therapeutics Largely Ignored: https://arizonadailyindependent.com/as-arizona-officials-push-vaccines-promising-therapeutics-largely-ignored/
$RLFTF (related) As Arizona Officials Push Vaccines Promising Therapeutics Largely Ignored: https://arizonadailyindependent.com/as-arizona-officials-push-vaccines-promising-therapeutics-largely-ignored/
I caught that 2.. good stuff!! 14 PEOPLE WHO WERE BASICALLY ABOUT TO DIE, RECEIVED IT (AVIPTADIL) AND ONLY TWO PASSED AWAY... 12/14 SURVIVED!!!!!!!!!!!
$RLFTF SICK > HELP SICK > HELP SICK > HELP
.. that's a 3 week number: Quote - Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?
$RLFTF AMAZING ..can't make sense of the FDA 'n whoever else getting in the way of making it easier for a DYING PERSON to try this, We're beyond BS Now, There is no argument .. I'm having a John Q (Denzel) Moment DYING RLF-100.. DYING RLF-100.. THAT'S IT DYING try ANYTHING
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:
“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.
Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?
As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.
Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.
The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.
The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.
Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”
https://thedispatch.com/p/fda-career-staff-are-delaying-the
- some replies -
Zaran
thank you, sorry state we are in
m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.
Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.
Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?
m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.
Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.
What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.
crymeariver
They should focus on saving dying people instead of vaccinating healthy people.
frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:
“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.
Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?
As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.
Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.
The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.
The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.
Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”
https://thedispatch.com/p/fda-career-staff-are-delaying-the
- some replies -
Zaran
thank you, sorry state we are in
m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.
Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.
Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?
m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.
Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.
What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.
crymeariver
They should focus on saving dying people instead of vaccinating healthy people.
frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?
Carlos and Bros. have a long history in Marijuana and I expect 'em to jump back in when permitted...
$LWLG Lightwave Logic to Present to Industry Audience at ECOC Exhibition 2020
Chief Executive Officer Michael Lebby to Present, Lead Market Focus Sessions on December 8th https://www.ecocexhibition.com/
ENGLEWOOD, CO – December 4, 2020 - Lightwave Logic, Inc. (OTCQB:LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced that management has been invited to present at the ECOC Exhibition 2020 taking place virtually December 7-9, 2020.
Elected in 2019 to chair the committee for ECOC’s Market Focus https://www.ecocexhibition.com/visit/market-focus/ sessions at the International Exhibition, Dr. Michael Lebby will introduce the program on behalf of Lightwave Logic. The agenda brings together leading technologists from around the world who represent major players in the optical communications field. The full agenda covers three days of speakers. https://www.ecocexhibition.com/visit/market-focus/market-focus-2020-timetable/
Furthermore, Dr. Michael Lebby, Chief Executive Officer of Lightwave Logic, is scheduled to host a virtual presentation entitled, “EO Polymer modulator platform with enhanced stability at both 1.3um and 1.5um” during the event as follows:
ECOC Exhibition 2020 - Market Focus
Date: Tuesday, December 8, 2020
Time: 4:00 p.m. Central European Time
For more information or to register for the ECOC Exhibition 2020, please visit the event website at www.ecocexhibition.com.
About Lightwave Logic, Inc.
Lightwave Logic, Inc. (OTCQB:LWLG) is developing a platform leveraging its proprietary engineered electro-optic (EO) polymers to transmit data at higher speeds with less power. The Company's high-activity and high-stability organic polymers allow Lightwave Logic to create next-generation photonic EO devices, which convert data from electrical signals into optical signals, for applications in data communications and telecommunications markets. For more information, please visit the Company's website at www.lightwavelogic.com.
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, lack of available funding; general economic and business conditions; competition from third parties; intellectual property rights of third parties; regulatory constraints; changes in technology and methods of marketing; delays in completing various engineering and manufacturing programs; changes in customer order patterns; changes in product mix; success in technological advances and delivering technological innovations; shortages in components; production delays due to performance quality issues with outsourced components; those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K and Form 10-Q; other risks to which our Company is subject; other factors beyond the Company's control.
Investor Relations Contact:
Greg Falesnik or Luke Zimmerman
MZ Group - MZ North America
949-385-6449
LWLG@mzgroup.us
www.mzgroup.us
Please click here to unsubscribe from future emails.